NCT04164199 2026-06-03Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesBeOne MedicinesPhase 3 Completed404 enrolled
NCT07426757 2026-06-01An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced CancersPfizerPhase 1 Recruiting120 enrolled